JP2015526441A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526441A5
JP2015526441A5 JP2015527566A JP2015527566A JP2015526441A5 JP 2015526441 A5 JP2015526441 A5 JP 2015526441A5 JP 2015527566 A JP2015527566 A JP 2015527566A JP 2015527566 A JP2015527566 A JP 2015527566A JP 2015526441 A5 JP2015526441 A5 JP 2015526441A5
Authority
JP
Japan
Prior art keywords
chloro
trifluoromethyl
indazol
benzoyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015527566A
Other languages
English (en)
Japanese (ja)
Other versions
JP6422438B2 (ja
JP2015526441A (ja
Filing date
Publication date
Priority claimed from PCT/CN2012/080131 external-priority patent/WO2014026327A1/en
Application filed filed Critical
Publication of JP2015526441A publication Critical patent/JP2015526441A/ja
Publication of JP2015526441A5 publication Critical patent/JP2015526441A5/ja
Application granted granted Critical
Publication of JP6422438B2 publication Critical patent/JP6422438B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015527566A 2012-08-15 2013-08-14 RORγT阻害剤としての4−ヘテロアリール置換安息香酸化合物およびその使用 Expired - Fee Related JP6422438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/080131 WO2014026327A1 (en) 2012-08-15 2012-08-15 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
CNPCT/CN2012/080131 2012-08-15
PCT/US2013/054887 WO2014028589A2 (en) 2012-08-15 2013-08-14 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2015526441A JP2015526441A (ja) 2015-09-10
JP2015526441A5 true JP2015526441A5 (OSRAM) 2016-09-23
JP6422438B2 JP6422438B2 (ja) 2018-11-14

Family

ID=50101185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015527566A Expired - Fee Related JP6422438B2 (ja) 2012-08-15 2013-08-14 RORγT阻害剤としての4−ヘテロアリール置換安息香酸化合物およびその使用

Country Status (11)

Country Link
US (2) US9745265B2 (OSRAM)
EP (1) EP2884981B1 (OSRAM)
JP (1) JP6422438B2 (OSRAM)
KR (1) KR20150042266A (OSRAM)
AU (1) AU2013302725A1 (OSRAM)
BR (1) BR112015003188A2 (OSRAM)
CA (1) CA2881688A1 (OSRAM)
IN (1) IN2015DN01156A (OSRAM)
MX (1) MX2015001941A (OSRAM)
RU (1) RU2015108894A (OSRAM)
WO (2) WO2014026327A1 (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
KR102408261B1 (ko) 2014-02-03 2022-06-10 비타이 파마슈티컬즈, 엘엘씨 Ror-감마의 디하이드로피롤로피리딘 저해제
WO2015131035A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
WO2015139621A1 (zh) * 2014-03-18 2015-09-24 北京韩美药品有限公司 4-杂芳基取代的苯甲酸或苯甲酰胺类化合物
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
TW201617314A (zh) * 2014-09-10 2016-05-16 第一三共股份有限公司 羧酸衍生物
WO2016044067A1 (en) * 2014-09-15 2016-03-24 Plexxikon Inc. Heterocyclic compounds and uses thereof
UA118989C2 (uk) * 2014-10-14 2019-04-10 Вітае Фармасьютікалс, Інк. Дигідропіролопіридинові інгібітори ror-гамма
GB201419015D0 (en) 2014-10-24 2014-12-10 Orca Pharmaceuticals Ltd Compounds
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
CA2973185C (en) * 2015-01-08 2021-02-16 Advinus Therapeutics Limited Bridgehead nitrogen bicyclic inhibitors/modulators of retinoic acid-related orphan receptor gamma (ror.gamma.)
EP3256450B1 (en) * 2015-02-11 2020-12-02 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
CN107614062A (zh) 2015-03-12 2018-01-19 加利福尼亚大学董事会 用RORγ抑制剂治疗癌症的方法
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションLycera Corporation RORγの作動薬及び疾患の療法として使用するジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物
KR20180025894A (ko) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
EP3353179B1 (en) * 2015-09-21 2022-02-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
AU2016344118A1 (en) * 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
RU2018117503A (ru) * 2015-10-27 2019-11-28 Мерк Шарп И Доум Корп. ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ
JP2018531957A (ja) * 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. RORγT阻害薬としての置換二環式ピラゾール化合物及びその使用
KR20180086221A (ko) 2015-11-20 2018-07-30 비타이 파마슈티컬즈, 인코포레이티드 Ror-감마의 조절물질
AU2017208998B2 (en) * 2016-01-21 2021-07-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Bruton's tyrosine kinase inhibitors
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ROR-γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN109789146B (zh) 2016-07-29 2023-04-18 拉普特医疗公司 趋化因子受体调节剂及其用途
US11628159B2 (en) 2017-01-10 2023-04-18 Eth Zurich Cell-protective compounds and their use
US11242335B2 (en) 2017-04-11 2022-02-08 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
WO2018219797A1 (en) 2017-06-02 2018-12-06 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
IL298639A (en) 2017-07-24 2023-01-01 Vitae Pharmaceuticals Llc Inhibitors of gamma ror
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
UY38144A (es) 2018-03-12 2019-10-31 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa
GB201811825D0 (en) * 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
AU2021245397A1 (en) * 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
CN117043162A (zh) * 2021-05-19 2023-11-10 迈巴制药(南京)有限公司 Tyk2选择性抑制剂及其用途
TW202345809A (zh) 2022-03-23 2023-12-01 美商愛德亞生物科學公司 作為parg抑制劑之經哌取代的吲唑化合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670447A (en) 1983-08-22 1987-06-02 Hoechst-Roussel Pharmaceuticals Inc. Antipsychotic 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
PT95899A (pt) * 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US6133290A (en) 1998-07-31 2000-10-17 Eli Lilly And Company 5-HT1F agonists
GB0117577D0 (en) 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
BRPI0514017A (pt) 2004-08-03 2008-05-27 Wyeth Corp indazóis úteis no tratamento de doenças cardiovasculares
CA2583428A1 (en) 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
SE0402762D0 (sv) 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
CN100516049C (zh) 2004-11-16 2009-07-22 永信药品工业股份有限公司 抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成
JP4954086B2 (ja) * 2004-12-08 2012-06-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 1h−ピロロ[2,3−b]ピリジン
US7696229B2 (en) 2006-02-17 2010-04-13 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
JP4675801B2 (ja) 2006-03-06 2011-04-27 日本メナード化粧品株式会社 Ror活性化剤
WO2007103308A2 (en) 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
PL2134685T3 (pl) 2007-04-16 2016-02-29 Abbvie Inc Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1
GB0708141D0 (en) 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
EP2155722B1 (en) 2007-06-05 2013-08-14 Merck Sharp & Dohme Corp. Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
US20100317863A1 (en) 2007-07-25 2010-12-16 Boehringer Ingelheim International Gmbh Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof
WO2010050837A1 (ru) 2008-10-28 2010-05-06 Haskin Lev Yakovlevich Ветроэнергетическая установка
EP2181710A1 (en) * 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体
EP2459184A1 (en) 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
AU2010330894A1 (en) 2009-12-18 2012-07-05 Janssen Pharmaceutica Nv Substituted aminothiazolone indazoles as estrogen related receptor-aalpha modulators
WO2011103189A1 (en) 2010-02-16 2011-08-25 Uwm Research Foundation, Inc. Methods of reducing virulence in bacteria
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9512111B2 (en) 2010-11-08 2016-12-06 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
KR20120063283A (ko) 2010-12-07 2012-06-15 제일약품주식회사 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
RU2620376C2 (ru) 2010-12-22 2017-05-25 Людвиг-Максимилианс-Университэт Мюнхен Цинкорганические комплексы, способы их получения и применение
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
JP2014166961A (ja) 2011-06-20 2014-09-11 Dainippon Sumitomo Pharma Co Ltd 新規インダゾール誘導体
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026328A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2015526441A5 (OSRAM)
RU2015108894A (ru) СОЕДИНЕНИЯ 4-ГЕТЕРОАРИЛЗАМЕЩЕННОЙ БЕНЗОЙНОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ RORгаммаТ И ИХ ПРИМЕНЕНИЯ
JP6862033B2 (ja) Gpr120アゴニストとしてのビアリール誘導体
HRP20171991T1 (hr) Derivati pirolidin karbonske kiseline kao agonisti g-protein spojenog receptora (gpr43), farmaceutski pripravak i postupci za primjenu u liječenju poremećaja metabolizma
JP6054869B2 (ja) 複素環化合物
RU2012116207A (ru) Производные индола в качестве модуляторов crac
JP2019537571A5 (OSRAM)
JP2017500364A5 (OSRAM)
JP2010508338A5 (OSRAM)
JP2010539186A5 (OSRAM)
TW201831464A (zh) 作為激酶抑制劑之雜環醯胺
JP2017526711A5 (OSRAM)
CA2873060A1 (en) Nampt inhibitors
HRP20170622T1 (hr) Derivati piridinila i kondenziranog piridinil triazolona
JP2019505595A5 (OSRAM)
WO2014181287A1 (en) Heterocyclyl compounds and uses thereof
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2016506964A5 (ja) ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド
JP2010533158A5 (OSRAM)
JP2016512515A5 (OSRAM)
JP2010539188A5 (OSRAM)
JP2014531465A5 (OSRAM)
JP2017524026A5 (OSRAM)
AU2014291711A1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
RU2013133800A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний